Domainex Ltd and SpiroChem AG have established a strategic fragment drug discovery collaboration that they will co-promote globally.   Under the terms of the agreement, Domainex will enrich its existing fragment collection with a diverse set of SpiroChem fragments that it will screen with its highly efficient and cost-effective FragmentBuilder platform. The SpiroChem-sourced fragments will provide unique chemical diversity, particularly in terms of three-dimensional chemotypes. The compa...